King Pharmaceuticals: PharmaVitae Profile

Publication Date	November 2007
Publisher	Datamonitor
Product Type	Report
Pages	107
ISBN Number	not applicable
Product Code	DAT03303

Price

£3,010.00
approximately: $4,470 | €3,542

PDF

PRINT £3,045 ($4,522 | €3,583)

Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark King's performance against key rivals in the ethical pharmaceutical sector
See how King's future depends on the success of its launch portfolio following the patent expiry of several of the company's key products

Content

Chapter 1 Executive Summary
- Key Findings
- Historical And Forecast Ethical Sales Performance
- Therapeutic Strategy
- Launch And Expiry Outlook
- Externalization, Geographic And Molecule Type Strategies
- Externalization Strategy
- Geographic Strategy
- Molecule Type Strategy
- Swot Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 2 Corporate History
- Key Findings
- Background
- Key Corporate Developments
- M&A History
- Medco Research And Jones Pharma Mergers
- Acquisition Of Meridian Medical Technologies And Elan's Primary Care Business
- Mylan Laboratories Terminates Acquisition Agreement
- Current Corporate Structure
- Pharmaceuticals
- Meridian Medical Technology
- Current Management Team
Chapter 3 Historical Performance
- Key Findings
- Introduction
- Revenue And Growth Rate Analysis, 2001-06
- Revenue And Growth Rate Vs. Peer Set
- Product Analysis, 2001-06
- Growth Drivers
- Skelaxin
- Altace
- Thrombin-Jmi
- Sonata
- Growth Resistors
- Rest Of Portfolio
- Operating Revenue And Cost Analysis, 2001-06
- Operating Revenue/Cost Analysis
Chapter 4 Forecast Performance
- Key Findings
- Introduction
- Revenue And Growth Rate, 2006-12
- Product Analysis, 2006-12
- Growth Drivers
- Altace Hctz
- Remoxy
- Avinza
- Growth Resistors
- Altace
- Skelaxin
- Thrombin-Jmi
- Sonata
- Therapy Area Analysis, 2006-12
- Therapy Area Growth Drivers
- Central Nervous System
- Therapy Area Growth Resistors
- Cardiovascular & Hematology
- Therapy Area Focus
- Launches And Expiries Analysis, 2006-12
- Launch Portfolio
- Avinza (Morphine Sulfate)
- Altace Hctz (Ramipril + Hydrochlorothiazide)
- Remoxy (Oxycodone)
- Core Portfolio
- Expiry Portfolio
- Thrombin-Jmi
- Altace
- Skelaxin
- Sonata
- Launch/Core/Expiry Configuration
- Externalization Analysis, 2006-12
- Geographic Analysis, 2006-12
- Molecule Type Analysis, 2006-12
Chapter 5 Key Products And Competitors
- Key Findings
- Overview
- Central Nervous System
- Avinza
- Overview
- Sales Forecast
- Newsflow
- Current Market Assessment
- Future Market Assessment
- Remoxy
- Overview
- Sales Forecast
- Newsflow
- Future Market Assessment
- Competitive Landscape
- Opioid Analgesics Market Dominated By Key Brands And Generic Competitors
- The Opioid Class: Potential For Abuse
- Skelaxin
- Overview
- Sales Forecast
- Newsflow
- Current Market Assessment
- Future Market Assessment
- Cardiovascular & Hematology
- Altace
- Overview
- Sales Forecast
- Newsflow
- Altace Hctz
- Overview
- Sales Forecast
- Newsflow
- R&D Pipeline
Chapter 6 Appendix
- Ims Vs. Company-Reported Data Reconciliation
- References
- Abbreviations
List Of Tables
- Table 1: King's Corporate Executive Committee
- Table 2: Peer Set Overview
- Table 3: Operating Revenue/Cost Analysis ($M), 2001-06
- Table 4: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
- Table 5: Product Portfolio Overview, Sales ($M), 2006-12
- Table 6: Therapy Area Overview, Sales ($M), 2006-12
- Table 7: Launch Portfolio Overview, Sales ($M), 2006-12
- Table 8: Core Portfolio Overview, Sales ($M), 2006-12
- Table 9: Expiry Portfolio Overview, Sales ($M), 2006-12
- Table 10: Externally Developed Portfolio ($M), 2006-12
- Table 11: Molecule Type Overview, Sales ($M), 2006-12
- Table 12: Key Products Overview
- Table 13: Avinza: Overview
- Table 14: Avinza: Sales Forecast ($M), 2006-12
- Table 15: Avinza: Newsflow
- Table 16: Remoxy: Overview
- Table 17: Remoxy: Sales Forecast ($M), 2006-12
- Table 18: Remoxy: Newsflow
- Table 19: Skelaxin: Overview
- Table 20: Skelaxin: Sales Forecast ($M), 2006-12
- Table 21: Skelaxin: Newsflow
- Table 22: Altace: Overview
- Table 23: Altace: Sales Forecast ($M), 2006-12
- Table 24: Altace: Newsflow
- Table 25: Altace Hctz: Overview
- Table 26: Altace Hctz: Sales Forecast ($M), 2006-12
- Table 27: Altace Hctz: Newsflow
- Table 28: King Pharmaceuticals Pipeline (Phase I-Registration)
List Of Figures
- Figure 1: Historical And Forecast Ethical Sales Performance (% Cagr), King Pharmaceuticals And Mid Pharma Peer Set
- Figure 2: Therapeutic Focus Vs. Mid Pharma Peer Set (%), 2006
- Figure 3: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), King Pharmaceuticals
- Figure 4: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Peer Set
- Figure 5: Key Strategic Products, Sales ($M), 2006-12
- Figure 6: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2006
- Figure 7: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2012
- Figure 8: Swot Analysis Of King Pharmaceuticals
- Figure 9: Current Corporate Structure
- Figure 10: Revenue & Growth Rate (Ethical Sales) ($M), 2001-06
- Figure 11: Ethical Revenue ($M) And Growth Rate (%) Vs. Peer Set, 2001-06
- Figure 12: Growth Drivers/Resistor Products Of Historical Revenue Performance ($M), 2001-06
- Figure 13: Operating Revenue/Cost Analysis ($M), 2001-06
- Figure 14: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
- Figure 15: Ethical Revenue ($M) And Growth Rate (%), 2006-12
- Figure 16: Top Five Products By Sales ($M), 2006
- Figure 17: Top Five Products By Sales ($M), 2012
- Figure 18: Growth Drivers And Resistors By Product, 2006-12
- Figure 19: Key Strategic Products, Sales ($M), 2006-12
- Figure 20: Ethical Sales By Therapy Area ($M), 2006-12
- Figure 21: Growth Drivers And Resistors By Therapy Area ($M), 2006-12
- Figure 22: Ethical Sales By Therapy Area (%), 2006-12
- Figure 23: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2006
- Figure 24: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2012
- Figure 25: Launch Schedule, Sales ($M), 2006-12
- Figure 26: Core Products Sales Growth ($M), 2006-12
- Figure 27: Expiry Schedule, Sales ($M), 2006-12
- Figure 28: Launch, Core And Expiry, Sales ($M), 2006-12
- Figure 29: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), King Pharmaceuticals
- Figure 30: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Peer Set
- Figure 31: Externalization Dependency, Sales ($M), 2006-12
- Figure 32: Growth Drivers And Resistors, Externally Vs. Internally Discovered Products, Sales ($M), 2006-12
- Figure 33: Externalization Dependency Vs. Peer Set, % Total Sales, 2006
- Figure 34: Externalization Dependency Vs. Peer Set, % Total Sales, 2012
- Figure 35: Geographical Sales Breakdown ($M), 2006-12
- Figure 36: Growth Drivers And Resistors By Geography, Sales ($M) 2006-12
- Figure 37: Us Dependency Vs. Peer Set, % Total Sales, 2006
- Figure 38: Us Dependency Vs. Peer Set, % Total Sales, 2012
- Figure 39: Molecule Type Sales Breakdown ($M), 2006-12
- Figure 40: Growth Drivers/ Resistors By Molecule Type, Sales ($M), 2006-12
- Figure 41: Biologics Dependency Vs. Peer Set, % Total Sales, 2006
- Figure 42: Biologics Dependency Vs. Peer Set, % Total Sales, 2012
- Figure 43: Ims Vs. Company-Reported Ethical Sales Discrepancy ($M), 2006
- Figure 44: Ims Vs. Company-Reported Ethical Sales Forecast Growth Rates (%), 2006-12